What Changed at Cadence

Every material change AI Health Index has tracked at Cadence: new modules, model and architecture updates, clinical evidence, regulatory status, security certifications, and integration depth. Each entry states what changed, cites its source, and carries our read on what it means for a buyer. The graded assessment of this vendor across all fifteen capability axes sits on its index profile.

Funding rounds, valuations, and awards are not product changes and are not logged here. Acquisitions appear only where there is direct product impact.

Impact

Type

1 entry

Showing changes for Cadence only.Show the full log

August 2026

C

Cadence

Aug 13, 2026

HighPartially Verified

Regulatory / FDA

Cadence announced that its HypertensionOS software was selected by the FDA as the second participant in the TEMPO for Digital Health Devices Pilot. The prescription Software as a Medical Device (SaMD) utilizes AI-assisted functionality to support clinician-supervised medication initiation and titration for patients with Stage 2 hypertension.

Our read

Participation in the TEMPO pilot enables Cadence to deploy its clinical AI medication management system under FDA enforcement discretion. This allows healthcare buyers to adopt the technology for bounded, automated chronic care workflows while contributing real-world evidence to regulatory frameworks.

Related axis: FDA and Regulatory StatusTrade pressView source